Role of daratumumab in the frontline management of multiple myeloma: a narrative review
Open Access
- 18 August 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 16 (10) , 743-760
Abstract
The prevalence of multiple myeloma (MM) has gradually increased over the last few decades in India due to growing population, better disease awareness and improved diagnostic procedures. Despite such advances, MM remains an incurable and relapsing disease due to its heterogeneity and genomic instability. With the inclusion of monoclonal antibodies, especially daratumumab in the frontline regimen, the management landscape of MM has improved significantly resulting in better disease control and patient outcomes. This review aims to provide an in-depth summary of efficacy and safety of frontline daratumumab therapy in treatment of MM including patients with high-risk cytogenetic profile. Based on the review of literature, daratumumab in frontline therapy has demonstrated improved efficacy in terms of reduction in disease progression or death, and superior minimal residual disease (MRD)-negativity rates with an acceptable safety profile in patients with newly diagnosed MM (NDMM) including patients with high-risk cytogenetic profile. Daratumumab alone or in combination with other drugs has shown similar clinical outcomes in patients with relapsed/refractory MM. Hence, daratumumab can be used upfront in patients with MM.Keywords
Funding Information
- funded by Johnson & Johnson Pvt Ltd, India
This publication has 99 references indexed in Scilit:
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-LinkingThe Journal of Immunology, 2016
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaBlood, 2016
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood, 2016
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibClinical Cancer Research, 2015
- Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical developmentTherapeutic Advances in Hematology, 2015
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomamAbs, 2015
- Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapyBlood, 2013
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011